Program
luxdegalutamide
Also written as “JSB462 Dose 1 QD”, “JSB462 Dose 2 QD” and “JSB462 QD”.
In Novartis’s pipeline, Androgen receptor protein degrader
. Its studies are mostly in Prostatic Neoplasms, led by Novartis.
Furthest: phase 2, since Sep 23, 20212 company-led studies, 2 open or runningNext primary completion: May 25, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 22 open or running | phase 2since Sep 23, 2021 | Sep 23, 2021 | May 25, 2027phase 2 · NCT05067140 |
- Named in Novartis’s own pipeline as
JSB462 (luxdegalutamide)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2021First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT05067140 · 164 enrolled · United States
- Sep 17, 2025Phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056 · 188 planned · United States, Australia, Canada and more
Ahead
- May 25, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT05067140
- Nov 9, 2029Primary completion: phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056
TargetBeta
“Androgen receptor protein degrader”the company's pipeline, read by Claude · source
“An orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand ”NCIt, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer · United States, Australia, Canada and more | 2 | Recruiting | Nov 9, 2029 | 188 |
| NCT05067140Prostatic Neoplasms · United States | 2 | Active, not recruiting | May 25, 2027 | 164 |
How it is read
Names in the registry
- “JSB462 Dose 1 QD”, 1 entry
- “JSB462 Dose 2 QD”, 1 entry
- “JSB462 QD”, 1 entry
- “ARV-766”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.